Alphabet’s AI unit Isomorphic inks drug discovery offers with Eli Lilly, Novartis for as much as $3B – Endpoints Information
Isomorphic Labs, Alphawager’s shutly watched AI beginup, has signed its first pharma halfnerships, and can work with Eli Lilly and Novartis in offers that might be value $3 billion, CEO Demis Hassabis exclusively advised Finishfactors Information.
Since its discovereding in November 2021, Isomorphic has fastly become a leading figure within the fast-growing AI biotech house. The Alphawager subsidiary is applying Google DeepThoughts’s biology research — particularly its professionaltein-structure predicting model AlphaFold — to drug discovery. Hassabis is CEO of Google DeepThoughts, the place he oversees Alphawager’s AI efforts, in addition to CEO of Isomorphic, which now employs about 90 people throughout its London headquarters and an office in Lausanne, Switzerland.
Unlock this text immediately by turning into a free subscriber.
You’ll get entry to free articles every month, plus you may customise what newsletters get delivered to your inbox every week, together with breaking information.